Predictors of response to Infliximab in children with luminal Crohn's disease

Journal of Crohn's and Colitis

Volumn 8, Issue 8, 2014, Pages 739-746

  Grover, Zubin ^a,b   Biron, Rebecca ^b   Carman, Nicholas ^b   Lewindon, Peter ^a,c  

^a Queensland Children's Medical Research Institute   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Crohn's disease; Immunomodulators; Infliximab; Loss of response; Paediatrics

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; CORTICOSTEROID; IMMUNOMODULATING AGENT; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ARTICLE; BODY MASS; BRONCHOSPASM; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DIZZINESS; DRUG DOSE INTENSIFICATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; ILEUM DISEASE; INFLUENZA; LETHARGY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME; ANTHROPOMETRIC PARAMETERS; BODY HEIGHT; CLINICAL EVALUATION; COLON SURGERY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FIBROSTENOTIC ILEAL DISEASE; FISTULISING CROHN DISEASE; HOT FLUSH; LOSE RESPONSE; LUMINAL CROHN DISEASE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; RECURRENT FEVER;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84904510856     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.12.017     Document Type: Article

References (31)

1. Goodhand J., Dawson R., Hefferon M., Tshuma N., Swanson G., Wahed M., et al. Inflammatory bowel disease in young people: the case for transitional clinics. Inflamm Bowel Dis 2010, 16:947-952.
2. Kanof M.E., Lake A.M., Bayless T.M. Decreased height velocity in children and adolescents before the diagnosis of Crohn''s disease. Gastroenterology 1988, 95:1523-1527.
3. Motil K.J., Grand R.J., Davis-Kraft L., Ferlic L.L., Smith E.O. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993, 105:681-691.
4. Sawczenko A., Ballinger A.B., Savage M.O., Sanderson I.R. Clinical features affecting final adult height in patients with pediatric-onset Crohn''s disease. Pediatrics 2006, 118:124-129.
5. Lee J., Escher J., Shuman M., Forbes P.W., Delemarre L.C., Harr B.W., et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis 2010, 16:1669-1677.
6. Burnham J.M., Shults J., Semeao E., Foster B.J., Zemel B.S., Stallings V.A., et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 2005, 82:413-420.
7. Schoon E.J., Blok B.M., Geerling B.J., Russell M.G., Stockbrugger R.W., Brummer R.J., et al. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000, 119:1203-1208.
8. Vernier-Massouille G., Balde M., Salleron J., Dupas J.L., Mouterde O., Merle V., et al. Natural history of pediatric crohn's disease: a population-based cohort study. Gastroenterology 2008, 135:1106-1113.
9. Van Limbergen J., Russell R.K., Drummond H.E., Aldhous M.C., Round N.K., Nimmo E.R., et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008, 135:1114-1122.
10. Pigneur B., Seksik P., Viola S., Viala J., Beaugerie L., Girardet J.P., et al. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010, 16:953-961.
11. Gisbert J., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn''s disease: a review. Am J Gastroenterol 2009, 104:760-767.
12. D'Haens G., Panaccione R., Higgins P., Vermeire S., Gassull M., Chowers Y., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106:199-212.
13. Ben-Horin S., Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn''s disease. Aliment Pharmacol Ther 2011, 33:987-995.
14. Crombé V., Salleron J., Savoye G., Dupas J.L., Vernier-Massouille G., Lerebours E., et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis Oct. 2011, 17:2144-2152.
15. de Ridder L., Rings E.H., Damen G.M., Kneepkens C.M., Schweizer J.J., Kokke F.T., et al. Infliximab dependency in pediatric Crohn''s disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008, 14:353-358.
16. Hyams J.S., Lerer T., Griffiths A., Pfefferkom M., Kugasthan S., Evans J., et al. Long-term outcome of maintenance Infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009, 15:816-822.
17. Duricova D., Pedersen N., Lenicek M., Hradsky O., Bronsky J., Adamcova M., et al. Infliximab dependency in children with Crohn's disease. Aliment Pharmacol Ther 2009, 29:792-799.
18. Van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010 Feb, 4:7-27.
19. Levine A., Griffiths A., Markowitz J., Wilson D.C., Turner D., Russell R.K., et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011, 17:1314-1321.
20. Cole T.J., Flegal K.M., Nicholls D., Jackson A.A., et al. Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ 2007, 335:194-202.
21. Hyams J., Ferry G., Mandel F., Gryboski J.D., Kibort P.M., Kirschner B.S., et al. Development and validation of paediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991, 12:439-447.
22. Hyams J., Markowitz J., Otley A., Rosh J., Mack D., Bousvaros A., et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005, 41:416-421.
23. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut March 2006, 55:426-431.
24. Solem C., Loftus E., Tremaine W., Harmsen W.S., Zinmeister A.R., Sandborn W.J., et al. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm Bowel Dis 2005, 11707-11712.
25. Daperno M., D''Haens G., Van Assche G., Baert F., Bulois P., Maunoury V., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
26. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology Mar 2007, 132:863-873.
27. Jürgens M., Mahachie John J.M., Cleynen I., Schnitzler F., Fidder H., van Moertkercke W., et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol May 2011, 9:421-427.
28. Reinisch W., Wang Y., Oddens B.J., Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther Mar 2012, 35(5):568-576.
29. Wine E., Reif S., Leshinsky-Silver E., Weiss B., Shaoul R.R., Shamir R., et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype and disease severity. Pediatrics 2004, 114:1281-1286.
30. Levine A., Shamir R., Wine E., Weiss B., Karban A., Shaoul R.R., et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn''s disease. Am J Gastroenterol 2005, 100:1598-1604.
31. Van Assche G., Magdelaine-Beuzelin C., D''Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn''s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.